Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 6, 2026, 01:35Alison Wright: BSGE 2026 Highlights Leadership Change and Future Vision
-
May 6, 2026, 01:30Short Menstrual Cycles May Signal Early Ovarian Ageing – Fertility Plus
-
May 6, 2026, 01:27Asma Khalil: Maternal Mental Health Remains a Leading Risk
-
May 5, 2026, 16:55Pregnancy Outcomes in a Recurrent Miscarriage Population After Uterine Surgeries – Fertility and Sterility
-
May 5, 2026, 16:43MAGENTA Oocyte Scores, Morphokinetics and Live Birth – Future Fertility
-
May 5, 2026, 16:34Join Us on 16 September to Explore Challenges in Managing a Successful Fertility Service – BFS
-
May 5, 2026, 16:17Mature Oocyte Retrieval Without an Exogenous Trigger During Stimulation – Fertility and Sterility
-
May 5, 2026, 16:08We Are Delighted to Announce that Fertility 2027 Registration Opens soon – Fertility Conferences
-
May 5, 2026, 15:59Lillian’s Story Highlights Urgency of Recognising Postpartum Preeclampsia – Preeclampsia Foundation